Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Wassilis S.C. Bruins, MDMSc, Wenrou Zheng, MSc, Jack P. Higgins, PhD, Erin K. Willert, PhD, John Newcomb, PhD, Ajeeta B Dash, PhD, Niels W.C.J. Van De Donk, MD PhD, Sonja Zweegman, MDPhD, Tuna Mutis, MD PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136928

Published: 2020

Journal Articles

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

Christie P.M. Verkleij, MD, Marloes Broekmans, Amy Wong, Sonja Zweegman, MDPhD, Raluca Verona, PhD, Homer Adams, III, PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141187

Published: 2020

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

Esther Drent, MSc, Maria Themeli, MD PhD, Renée Poels, Niels W.C.J. van de Donk, MD PhD, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD

Blood (2016) 128 (22): 2170.

https://doi.org/10.1182/blood.V128.22.2170.2170

Published: 2016

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Monique C. Minnema, MD PhD, Sanne de Haart, MD, Tuna Mutis, MD PhD, Marco Koudijs, PhD, Marja van Blokland, Henk Lokhorst, MD PhD, Roel de Weger, MD PhD, Stefan Willems, MD PhD

Blood (2015) 126 (23): 4174.

https://doi.org/10.1182/blood.V126.23.4174.4174

Published: 2015

Journal Articles

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Laurens E. Franssen, MD, Maarten E. Emmelot, BSc, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 2005.

https://doi.org/10.1182/blood.V122.21.2005.2005

Published: 2013

Journal Articles

Improved Vaccine Design For Adoptive Immunotherapy In Hematological Malignancies Through Chemically Modified Minor Histocompatibility Antigen Epitopes

Rimke Oostvogels, MD, Rieuwert Hoppes, Henk Lokhorst, Robbert M Spaapen, PhD, Huib Ovaa, PhD, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 5435.

https://doi.org/10.1182/blood.V122.21.5435.5435

Published: 2013

Journal Articles

The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model

Sanne J. de Haart, MD, Monique C. Minnema, MD PhD, Julie H. Huang, PhD, Tineke Aarts-Riemens, Henk Lokhorst, Anton Martens, PhD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 3250.

https://doi.org/10.1182/blood.V122.21.3250.3250

Published: 2013

Journal Articles

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Inger S. Nijhof, MD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Berris van Kessel, Joost M. Bakker, PhD, Paul W.H.I. Parren, PhD, Richard W.J. Groen, PhD, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2013) 122 (21): 277.

https://doi.org/10.1182/blood.V122.21.277.277

Published: 2013

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape

Zandra K. Klippel, MD, Jeffrey Chou, MD, PhD, Andrea M. H. Towlerton, Paul F Robbins, PhD, Lilien Voong, William I. Bensinger, MD, H. Lokhorst, Tuna Mutis, MD, PhD, Lihua Elizabeth Budde, MD, PhD, Edus H. Warren, III, MD, PhD

Blood (2013) 122 (21): 4205.

https://doi.org/10.1182/blood.V122.21.4205.4205

Published: 2013

Journal Articles

Epigenetic Regulation of Cancer-Testis Antigen Expression in Multiple Myeloma and Correlation with High-Risk Cytogenetics.

Zandra K. Klippel, MD, Akshay Srivatsan, Andrea M. H. Towlerton, Jeffrey Chou, MD, PhD, Tuna Mutis, MD PhD, Henk Lokhorst, William I. Bensinger, MD, Edus H. Warren, III, MD, PhD

Blood (2012) 120 (21): 2923.

https://doi.org/10.1182/blood.V120.21.2923.2923

Published: 2012

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Andries C Bloem, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 940.

https://doi.org/10.1182/blood.V120.21.940.940

Published: 2012

Journal Articles

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Inger S. Nijhof, MD, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, PhD, Paul W. H. I. Parren, PhD, Henk Lokhorst, MD, PhD, Tuna Mutis, MD PhD

Blood (2012) 120 (21): 4988.

https://doi.org/10.1182/blood.V120.21.4988.4988

Published: 2012

Journal Articles

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 1834.

https://doi.org/10.1182/blood.V120.21.1834.1834

Published: 2012

Journal Articles

Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),

Sanne J de Haart, MD, Monique C. Minnema, MD PhD, Tineke Aarts-Riemens, Niels Bovenschen, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 4039.

https://doi.org/10.1182/blood.V118.21.4039.4039

Published: 2011

Journal Articles

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Richard W Groen, PhD, Willy A Noort, PhD, Reinier Raymakers, MD, PhD, Henk-Jan Prins, Msc, Linda Aalders, Frans M Hofhuis, Berris van Kessel, Petra Moerer, Henk Rozemuller, PhD, Jan J. Schuringa, PhD, Joost de Bruijn, PhD, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD, Anton CM Martens, PhD

Blood (2011) 118 (21): 3412.

https://doi.org/10.1182/blood.V118.21.3412.3412

Published: 2011

NARROW

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Improved Vaccine Design For Adoptive Immunotherapy In Hematological Malignancies Through Chemically Modified Minor Histocompatibility Antigen Epitopes

The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape

Epigenetic Regulation of Cancer-Testis Antigen Expression in Multiple Myeloma and Correlation with High-Risk Cytogenetics.

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only